Área Metabolismo

Nutrition and Metabolism Translational Research Group

Antonio Hernández Mijares

Dr. Hernández Mijares completed his studies in Medicine in the Faculty of Medicine at the University of Valencia in 1973, completing his senior graduate degree (Master’s equivalent) thesis that year. He obtained his doctorate with cum laude honors in 1988, at the same university. 

He obtained a placement as the resident doctor (via public civil servant exams) in the General Pathology Service at the Hospital Clínico Universitario in Valencia, and continued in this position until November 1976. He subsequently obtained the Consultant Medical Doctor position in the same service, and in 1982 obtained a position as the Senior Professor Medical Specialist in the Nutrition and Endocrinology Service at the Hospital Clínico Universitario in Valencia. In October 1995 Dr. Hernández became the Head of the Endocrinology and Nutrition Section at the Hospital Universitario Dr. Peset in Valencia (via public civil servant exams) where he currently resides. He obtained accreditation as a Medical Doctor Specialist in Internal Medicine in 1977 and as a Medical Specialist Doctor in Nutrition and Endocrinology in 1983.

Dr. Hernández began his teaching activity as a collaborating teacher, parallel to his medical attendance activities carried out at the Hospital Clínico Universitario in Valencia. In 1991 he obtained a position as an Associate Professor in the Medicine Department at the University of Valencia and in 2010 he obtained a permanent Senior Professorship at the University in the same department. 

His research activity focuses on studying insulin resistance states —diabetes, obesity, metabolic syndrome, and polycystic ovary syndrome (PCOS), lipid metabolism and cardiovascular risk, as well as oxidative stress and endothelial dysfunction in the abovementioned states. He won a grant from the national Carlos III Health Institute Healthcare Research Fund (FIS; Fondo de Investigación Sanitaria) in order to extend his research at the Endocrine Research Unit in the Mayo Clinic, Rochester MN, USA, in 1994. He has developed twelve competitive research projects, granted by official bodies, as a Principal Investigator including two contracts for Research Activity Intensification from the National Health System. 

Dr. Hernández has over 250 publications in national and international journals, more than 580 communications and conference lectures in his medical specialty, and he has directed 19 doctoral theses. He received the Bancaixa Foundation Award for research work and the García-Conde Foundation Award from the Valencian Autonomous Community’s Royal Academy of Medicine and Science (RAMCV; Reial Acadèmia de Medicina i Ciències de la Comunitat Valenciana) for research on diabetes mellitus. 

He is currently the Chairman of the Investigation Commission for the Valencian regional government’s Peset-Health Department, a member of the scientific committee for the Valencian Autonomous Community’s Foundation for the Promotion of Health and Biomedical Research, and the Principal Investigator of INCLIVA Health Research Institute’s Nutrition and Metabolism Translational Research Group. 


Nutrition and Metabolism Translational Research Group

Collaborating Researcher

Víctor Manuel Víctor González
Eva Solá Izquierdo
Ana Jover Fernández
Nadezda Apostolova Atanasovska
Milagros Rocha Barajas
Marcelino Gómez Balaguer
Juan Vicente Esplugues Mota
Carlos Morillas Ariño

Pre-doctoral researcher

Susana Rovira Llopis


Antonio Hernández Mijares


Lorena Bellod Lázaro
Celia Bañuls Morant

• The group has proven that there is a correlation between mitochondrial dysfunction and leukocyte-endothelial interaction in diabetic patients which is more marked in patients with silent ischemic cardiopathy (SIC). 

• In turn, a direct correlation between the presence of diabetic nephropathy, the leukocyte-endothelial interaction, and myeloperoxidase levels has also been shown. The group identified myeloperoxidase as a fundamental target for treating diabetic nephropathy. 

• In addition, they have demonstrated that women with PCOS have lower high-density lipoprotein (HDL) and apolipoprotein A-I levels, whereas obese patients show lipid profiles typical of atherogenic dyslipidemia.